Lantern Pharma Announces Upcoming Conference Presentations

PR Newswire

DALLAS, Nov. 24, 2020 /PRNewswire/ — Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform the pace, risk and cost of oncology drug discovery and development, and identify patients who will benefit from its targeted oncology drug candidates, announced that Panna Sharma, CEO and President, will participate in the following investor events in December:

  1. Diamond Equity Research Emerging Growth Invitational
    Date/time: December 1, 2020 at 12:20 pm ET
    Zoom Link for Live Event: https://us02web.zoom.us/webinar/register/WN_2S0ftHykTdSY_7HJCjGZAQ

  2. hubXchange Virtual US East Coast AI in Drug Discovery Xchange
    Date/time: December 2, 2020 at 12:20 pm ET
    Location: https://www.hub-xchange.com/ai-in-drug-discovery-2020

  3. 2020 Benzinga Global Small Cap Conference
    Date/time: December 9, 2020 at 3:30 p.m. ET
    Zoom Link for Live Event: https://us02web.zoom.us/j/89571252065

All meetings and presentations will be held virtually. Investors and media interested in meeting with Panna Sharma should contact Marek Ciszewski, J.D., at: [email protected] or +1.628.777.3167. Registered conference attendees may also request meetings through the respective conference registration system.

About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern’s focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company’s website at www.lanternpharma.com or follow the company on Twitter @lanternpharma

Contact:
Marek Ciszewski, JD
Director, Investor Relations
628-777-3167
[email protected]

Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this press release include, among other things, statements relating to: the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of any of our drug candidates; our strategic plans to expand the number of data points that our RADR® platform can access and analyze; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements to the effect that Lantern Pharma Inc. or our management “believes,” “expects,” “anticipates,” “estimates,” “plans” (and similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as the impact of the COVID-19 pandemic, the results of our clinical trials, and the impact of competition. Additional factors can be found in the Risk Factors section in our final prospectus, dated June 10, 2020, for our initial public offering, on file with the Securities and Exchange Commission. You may access our June 10, 2020 final prospectus under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-announces-upcoming-conference-presentations-301179612.html

SOURCE Lantern Pharma

The Green Organic Dutchman Receives Health Canada Approval to Export Medical Cannabis to Europe

PR Newswire

TORONTO, Nov. 24, 2020 /PRNewswire/ – The Green Organic Dutchman Holdings Ltd. (“TGOD” or the “Company”) (TSX: TGOD) (US: TGODF), a leading producer of premium certified organically grown cannabis, is pleased to announce that it has received an Export Certificate from Health Canada.  This certificate enables TGOD to complete its first shipment of medical cannabis to Germany where it will undergo stability testing, the last step before the Company can commence commercialization in 2021.

“This is an important milestone as we get ready to begin the international shipping of our certified organically grown medical cannabis products.  Germany is the first of several markets that we are planning to supply.  Other countries that we anticipate shipping to in the future are Australia and Mexico,” commented Sean Bovingdon, Interim CEO of TGOD.  “We chose to obtain our EU-GMP certification from Germany because of its high standards and its progressive medical cannabis framework,” added Bovingdon.

About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US–OTC: TGODF) is a premium certified organically grown cannabis company focused on the health and wellness market.  Its organic cannabis is cultivated in living soil, as nature intended.  The Company is committed to cultivating a better tomorrow by producing its products responsibly, with less waste and impact on the environment. Its two Canadian facilities have been built to LEED certification standards and its products are sold in recyclable packaging.  In Canada, TGOD sells dried flower and oil, and recently launched a series of next–generation cannabis products such as hash, vapes, organic teas and dissolvable powders.  Through its European subsidiary, HemPoland, the Company also distributes premium hemp CBD oil and CBD-infused topicals in Europe. By leveraging science and technology, TGOD harnesses the power of nature from seed to sale.

TGOD’s Common Shares and warrants issued under the indentures dated November 1, 2017, December 19, 2019, June 12, 2020 and October 23, 2020 trade on the TSX under the symbol “TGOD”, “TGOD.WT”, “TGOD.WS”, “TGOD.WR” and “TGOD.WA”, respectively, and TGODF trades in the US on the OTCQX. For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.

Cautionary Statements

This news release includes statements containing certain “forward–looking information” within the meaning of applicable securities law (“forward–looking statements”). Forward looking statements in this release include, but are not limited to, statements about the completion of validation of the Company’s products for international export, statements about the export of the Company’s medical products for commercial purposes to Germany and other jurisdictions, statements about the timing of international sales of the Company’s products and statements about the Company’s ability to offer certain products in certain jurisdictions.  Forward–looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “should”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions.  Various assumptions were used in drawing the conclusions or making the projections contained in the forward–looking statements throughout this news release. Forward–looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties (including market conditions) and other factors that could cause actual events or results to differ materially from those projected in the forward–looking statements, including those risk factors described in the Company’s most recently filed Annual Information Form available on SEDAR.  The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the TSX nor the TSX’s Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/the-green-organic-dutchman-receives-health-canada-approval-to-export-medical-cannabis-to-europe-301179410.html

SOURCE The Green Organic Dutchman Holdings Ltd.

Salesforce to Hold Annual Investor Day on December 8, 2020

Investor Day to be broadcast live on Salesforce’s investor relations website

PR Newswire

SAN FRANCISCO, Nov. 24, 2020 /PRNewswire/ — Salesforce (NYSE: CRM), the global leader in CRM, today announced that it will hold its annual Investor Day on Tuesday, Dec. 8 beginning at 10:30 a.m. (PT) / 1:30 p.m. (ET).

The live broadcast and on-demand replay will be available at www.salesforce.com/investorday2020 and at www.salesforce.com/investor. An investor presentation accompanying the program will also be made available at www.salesforce.com/investor at approximately 12:00 p.m. PT on Dec. 8, 2020.

About Salesforce
Salesforce is the global leader in Customer Relationship Management (CRM), bringing companies closer to their customers in the digital age. Founded in 1999, Salesforce enables companies of every size and industry to take advantage of powerful technologies—cloud, mobile, social, internet of things, artificial intelligence, voice and blockchain—to create a 360-degree view of their customers. For more information about Salesforce (NYSE: CRM), visit: www.salesforce.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/salesforce-to-hold-annual-investor-day-on-december-8-2020-301179494.html

SOURCE Salesforce

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

PR Newswire

NEW YORK, Nov. 24, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.

Digital therapeutics are defined as evidence-based therapeutic interventions for patients to prevent, manage, or treat a mental disorder or disease. Pairing digital tools, such as wearables and the latest in machine learning, with psychedelic assisted therapies, can give healthcare providers the ability to optimize and better understand the patient journey and therapeutic outcomes from pre-care through to after-care.

MindMed Co-Founder and Co-CEO J.R. Rahn said, “We believe that the next frontier in psychedelic medicine will be to quantify with great precision psychedelic assisted therapy’s impact on patient populations. This new division will not only build apps, technologies and other platforms to help the patient, but hopefully also make the medical community comfortable with this novel treatment paradigm for mental health and addiction by measuring the potential value to their patient populations and ultimate savings to insurers.”

Recent advancements in digital therapeutics have the potential to enable a real time assessment of efficacy in both clinical trials and real-world settings leading to a more robust understanding of the value of a treatment and long-term impact on patient outcomes.

MindMed’s clinical team under the leadership of President and Head of Clinical Dr. Miri Halperin Wernli is designing an experimental clinical trial that pairs non-hallucinogenic psychedelic inspired medicines such as microdoses of LSD with digital therapeutics to track, engage and influence patient behavior. MindMed intends to announce full details of this clinical trial once MindMed and its scientific collaborators finalize the protocol design for submission to relevant health regulators.

Dr. Miri Halperin Wernli said, “This is a perfect moment for digital medicine solutions to come to patients to help support behavioral change, measure and enhance psychiatric care and health outcomes. Our intention is to use digital therapeutics alongside pharmaceutical medicines to maximize one another’s value to the patient and for the healthcare system. The two classes of medicine, along with psychotherapy and various forms of cognitive behavioral therapies, must be regarded as complementary to enhance outcomes, which will create new opportunities to improve quality of care and patient outcomes and drive behavior change at scale.”


About MindMed

MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the company’s groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.

MindMed trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ. For more information: www.mindmed.co


MindMed Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and performance of Mind Medicine (MindMed) Inc. (“MindMed”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs, MindMed’s ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, ” Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of Products and Product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Product candidates and new indications for Products; unforeseen safety issues resulting from the administration of Products and Product candidates in patients, including serious complications or side effects in connection with the use of MindMed’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed’s ability to continue to develop or commercialize Products; ongoing regulatory obligations and oversight impacting Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of Products and Product candidates and the impact of studies on the commercial success of Products and Product candidates; the availability and extent of reimbursement of Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; competing drugs and product candidates that may be superior to Products and Product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to MindMed and its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed’s business, prospects, operating results, and financial condition. Any forward-looking statements are made based on management’s current beliefs and judgment. MindMed does not undertake any obligation to update publicly any forward-looking statement.

Media Contact:
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/mindmed-to-launch-albert-a-digital-medicine-division-for-psychedelic-medicines-301179498.html

SOURCE Mind Medicine (MindMed) Inc.

DICK’S Sporting Goods Reports Third Quarter Results; Delivers Record-Setting 23.2% Increase in Same Store Sales

– Third quarter 2020 earnings per diluted share of $1.84 increased 179% versus $0.66 per diluted share in the prior year; on a non-GAAP basis, earnings per diluted share of $2.01 increased 287% versus $0.52 per diluted share in the prior year

– eCommerce sales increased 95% during the third quarter of 2020 as compared to the third quarter of 2019

– Brick-and-mortar same store sales increased double-digits during the third quarter of 2020, the Company’s best performance since going public nearly two decades ago

– Company is in a strong financial position, ending the quarter with nearly $1.1 billion of cash and cash equivalents and no outstanding borrowings on its $1.855 billion revolving credit facility

PR Newswire

PITTSBURGH, Nov. 24, 2020 /PRNewswire/ — DICK’S Sporting Goods, Inc. (NYSE: DKS), the largest U.S. based full-line omni-channel sporting goods retailer, today reported sales and earnings results for the third quarter ended October 31, 2020.


Third Quarter Results

The Company reported consolidated net income for the third quarter ended October 31, 2020 of $177.2 million, or $1.84 per diluted share. As a result of actions taken to prioritize the health and well-being of its teammates and athletes, the Company incurred approximately $48 million of pre-tax incremental teammate compensation and safety costs in response to COVID-19, or $0.37 per diluted share, net of tax, during the current quarter. The Company reported consolidated net income for the third quarter ended November 2, 2019 of $57.6 million, or $0.66 per diluted share.

On a non-GAAP basis, the Company reported consolidated net income for the quarter ended October 31, 2020 of $182.2 million, or $2.01 per diluted share, which excluded non-cash amortization of the debt discount associated with the Company’s convertible senior notes and included the share impact of the convertible note hedge purchased by the Company, which is antidilutive for GAAP purposes. For the third quarter ended November 2, 2019, the Company reported consolidated net income on a non-GAAP basis of $44.8 million, or $0.52 per diluted share. Third quarter 2019 results exclude the gain on sale of subsidiaries, charges related to the exit of eight Field & Stream stores, and a non-cash asset impairment. The GAAP to non-GAAP reconciliations are included in a table later in the release under the heading “GAAP to Non-GAAP Reconciliations.”

Net sales for the third quarter of 2020 were $2.41 billion, an increase of 22.9% compared to the third quarter of 2019. This increase was driven by a 23.2% increase in consolidated same store sales and included an increase in eCommerce sales of 95%. eCommerce penetration for the third quarter of 2020 was approximately 21% of total net sales, compared to approximately 13% during the third quarter of 2019. Third quarter 2019 consolidated same store sales increased 6.0%.

“We had another exceptionally strong quarter from both a sales and a profitability perspective. The strength of our diverse category portfolio once again helped us capitalize on the favorable shifts in consumer demand, as the positive trends across golf, outdoor activities, home fitness and active lifestyle continued throughout Q3,” said Edward W. Stack, Chairman and Chief Executive Officer. “Our performance in the quarter was driven by our 45,000 dedicated teammates who continued to work hard every day to safely serve our athletes and communities.”

Lauren R. Hobart, President, added, “Our stores continue to be the hub of our industry-leading omni-channel platform and were the key to our unprecedented third quarter growth. Brick-and-mortar store comps grew double-digits, and our stores fulfilled approximately 70% of our online sales, which increased nearly 100% for the quarter. In fact, our stores drove 90% of our total Q3 sales growth, whether an athlete purchased at the register, picked up curbside or had their order delivered through ship-from-store. Data science and technology will continue to play an important role in creating a personalized, one-to-one relationship with our athletes, enabling us to serve them in the most convenient way possible.”

Mr. Stack concluded, “Overall, the favorable trends in our business have continued into Q4. These strong sales results have been partially offset by warmer weather that has negatively impacted sales in important cold-weather categories. Taken together, through the first three weeks of Q4, our consolidated comp sales have increased in the high-teens.”


Balance Sheet

The Company ended the third quarter of 2020 with nearly $1.1 billion in cash and cash equivalents and no outstanding borrowings under its $1.855 billion revolving credit facility. In April, the Company issued $575 million aggregate principal amount of 3.25% Convertible Senior Notes, which added over $500 million of net proceeds to its cash position.

Total inventory decreased 9.8% at the end of the third quarter of 2020 as compared to the end of the third quarter of 2019.


Year-to-Date Results

The Company reported consolidated net income for the 39 weeks ended October 31, 2020 of $310.6 million, or $3.44 per diluted share. As a result of actions taken to prioritize the health and well-being of its teammates and athletes in response to COVID-19, the Company incurred approximately $124 million of pre-tax incremental teammate compensation and safety costs, or $1.01 per diluted share, net of tax, during the 39 weeks ended October 31, 2020. For the 39 weeks ended November 2, 2019, the Company reported consolidated net income of $227.6 million, or $2.53 per diluted share.

On a non-GAAP basis, the Company reported consolidated net income for the 39 weeks ended October 31, 2020 of $321.3 million, or $3.65 per diluted share, which excluded non-cash amortization of the debt discount associated with the Company’s convertible senior notes and included the share impact of the convertible note hedge purchased by the Company, which is antidilutive for GAAP purposes. For the 39 weeks ended November 2, 2019, the Company reported consolidated net income on a non-GAAP basis of $215.8 million, or $2.39 per diluted share, which excludes the gain on sale of subsidiaries, non-cash asset impairments, charges related to the exit of eight Field & Stream stores, and the favorable settlement of a litigation contingency. The GAAP to non-GAAP reconciliations are included in a table later in the release under the heading “GAAP to Non-GAAP Reconciliations.”

Net sales for the 39 weeks ended October 31, 2020 increased 5.2% to approximately $6.46 billion. Despite temporary store closures during March, April and May to help prevent the spread of COVID-19, consolidated same store sales increased 5.8%. eCommerce sales increased 135%. eCommerce penetration for the 39 weeks ended October 31, 2020 was approximately 28% of total net sales, compared to approximately 13% during the 39 weeks ended November 2, 2019. Consolidated same store sales increased 3.1% for the 39 weeks ended November 2, 2019.


Capital Allocation

On November 20, 2020, the Company’s Board of Directors authorized and declared a quarterly dividend in the amount of $0.3125 per share on the Company’s Common Stock and Class B Common Stock. The dividend is payable in cash on December 29, 2020 to stockholders of record at the close of business on December 11, 2020.

For the 39 weeks ended October 31, 2020, capital expenditures totaled $156.4 million on a gross basis, or $114.1 million net of deferred construction allowances provided by landlords. For the 39 weeks ended November 2, 2019, capital expenditures totaled $165.7 million on a gross basis, or $140.1 million net of deferred construction allowances provided by landlords.


Full Year 2020 Outlook

As previously announced on March 19, 2020, the Company withdrew its fiscal 2020 outlook. The Company is not providing an updated outlook at this time.


Conference Call Info

The Company will host a conference call today at 10:00 a.m. Eastern Time to discuss the third quarter results. Investors will have the opportunity to listen to the earnings conference call over the internet through the Company’s website located at investors.DICKS.com. To listen to the live call, please go to the website at least fifteen minutes early to register, download, and install any necessary audio software. For those who cannot listen to the live webcast, it will be archived on the Company’s website for approximately twelve months.


Non-GAAP Financial Measures

In addition to reporting the Company’s financial results in accordance with generally accepted accounting principles (“GAAP”), the Company reports certain financial results that differ from what is reported under GAAP. These non-GAAP financial measures include consolidated non-GAAP net income, non-GAAP earnings per diluted share, and net capital expenditures, which management believes provides investors with useful supplemental information to evaluate the Company’s ongoing operations and to compare with past and future periods. Management believes that excluding non-cash debt discount amortization from its convertible senior notes and including the share impact from the convertible note hedge is useful to investors because it provides a more complete view of the economics of the transaction. Management also uses certain non-GAAP measures internally for forecasting, budgeting, and measuring its operating performance. These measures should be viewed as supplementing, and not as an alternative or substitute for, the Company’s financial results prepared in accordance with GAAP. The methods used by the Company to calculate its non-GAAP financial measures may differ significantly from methods used by other companies to compute similar measures. As a result, any non-GAAP financial measures presented herein may not be comparable to similar measures provided by other companies. A reconciliation of the Company’s non-GAAP measures to the most directly comparable GAAP financial measures are provided below and on the Company’s website at investors.DICKS.com.


Fiscal 2020 Consolidated Same Store Sales

Consolidated same store sales include stores that were temporarily closed as a result of COVID-19. The method of calculating consolidated same store sales varies across the retail industry, including the treatment of temporary store closures as a result of COVID-19. Accordingly, our method of calculating this metric may not be the same as other retailers’ methods. For additional information on consolidated same store sales, please see our most recent Annual Report on Form 10-K, and any subsequent Quarterly Reports on Form 10-Q, filed with the Securities and Exchange Commission.


Forward-Looking Statements Involving Known and Unknown Risks and Uncertainties

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties and change based on various important factors, many of which may be beyond the Company’s control. The Company’s future performance and actual results may differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements should not be relied upon by investors as a prediction of actual results. Forward-looking statements include statements regarding, among other things, the Company’s future performance, liquidity, and share repurchases and dividends.

Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements include, but are not limited to: the impact on our business, operations and financial results due to the duration and scope of the COVID-19 pandemic, including whether there is a second wave or periods of increases in the number of COVID-19 cases in areas in which we operate, and the restrictions imposed by federal, state, and local governments in response to the pandemic; changes in consumer discretionary spending, including those caused by COVID-19; the extent to which changes in consumer demand due to the COVID-19 pandemic will continue and whether new trends will emerge after the impact of the COVID-19 pandemic subsides; store closures and other impacts to our business resulting from civil disturbances; investments in omni-channel growth not producing the anticipated benefits within the expected time-frame or at all; risks relating to private brands and new retail concepts; investments in business transformation initiatives not producing the anticipated benefits within the expected time-frame or at all; the amount devoted to strategic investments and the timing and success of those investments; the results of the strategic review of the hunt business, including Field & Stream; inventory turn; changes in the competitive market and competition amongst retailers, including an increase in promotional activity; changes in consumer demand or shopping patterns and the ability to identify new trends and have the right trending products in stores and online, including changes caused by COVID-19; changes in existing tax, labor, foreign trade and other laws and regulations, including those imposing new taxes, surcharges, or tariffs; limitations on the availability of attractive retail store sites; unauthorized disclosure of sensitive or confidential customer information; website downtime, disruptions or other problems with the eCommerce platform, including interruptions, delays or downtime caused by high volumes of users or transactions, deficiencies in design or implementation, or platform enhancements; disruptions or other problems with information systems; factors affecting vendors, including supply chain and currency risks; talent needs and the loss of Edward W. Stack, Chairman and Chief Executive Officer; developments with sports leagues, professional athletes or sports superstars, including disruptions and cancellations due to COVID-19; weather-related disruptions and seasonality of the Company’s business; and risks associated with being a controlled company.

For additional information on these and other factors that could affect the Company’s actual results, see the risk factors set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the most recent Annual Report filed with the SEC on March 20, 2020 and our Quarterly Report filed with the SEC on August 26, 2020. The Company disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation. Forward-looking statements included in this release are made as of the date of this release.


About DICK’S Sporting Goods, Inc.

Founded in 1948, DICK’S Sporting Goods, Inc. is a leading omni-channel sporting goods retailer offering an extensive assortment of authentic, high-quality sports equipment, apparel, footwear and accessories. As of October 31, 2020, the Company operated 732 DICK’S Sporting Goods locations across the United States, serving and inspiring athletes and outdoor enthusiasts to achieve their personal best through a blend of dedicated teammates, in-store services and unique specialty shop-in-shops dedicated to Team Sports, Athletic Apparel, Golf, Lodge/Outdoor, Fitness and Footwear.

Headquartered in Pittsburgh, PA, DICK’S also owns and operates Golf Galaxy and Field & Stream specialty stores, as well as GameChanger, a youth sports mobile app for scheduling, communications and live scorekeeping. DICK’S offers its products through a dynamic eCommerce platform that is integrated with its store network and provides customers with the convenience and expertise of a 24-hour storefront. For more information, visit the Investor Relations page at dicks.com.


Contacts:

Investor Relations:
Nate Gilch, Senior Director of Investor Relations
DICK’S Sporting Goods, Inc.
[email protected]
(724) 273-3400

Media Relations:
(724) 273-5552 or [email protected]

Category: Financial


DICK’S SPORTING GOODS, INC. AND SUBSIDIARIES


CONSOLIDATED STATEMENTS OF INCOME – UNAUDITED


(In thousands, except per share data)


13 Weeks Ended


October 31,

2020


% of


Sales(2)


November 2,

2019


% of


Sales(2)

Net sales

$

2,412,112

100.00

%

$

1,962,204

100.00

%

Cost of goods sold, including occupancy and
distribution costs (1)

1,569,938

65.09

1,381,562

70.41

GROSS PROFIT

842,174

34.91

580,642

29.59

Selling, general and administrative expenses

591,117

24.51

531,704

27.10

Pre-opening expenses

4,964

0.21

3,313

0.17

INCOME FROM OPERATIONS

246,093

10.20

45,625

2.33

(Gain) Loss on sale of subsidiaries

(33,779)

(1.72)

Interest expense

12,769

0.53

4,278

0.22

Other (income) expense

(3,746)

(0.16)

(2,020)

(0.10)

INCOME BEFORE INCOME TAXES

237,070

9.83

77,146

3.93

Provision for income taxes

59,854

2.48

19,562

1.00

NET INCOME

$

177,216

7.35

%

$

57,584

2.93

%

EARNINGS PER COMMON SHARE:

Basic

$

2.10

$

0.68

Diluted

$

1.84

$

0.66

WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING:

Basic

84,422

85,048

Diluted

96,571

86,601


(1) Cost of goods sold includes: the cost of merchandise (inclusive of vendor allowances, inventory shrinkage and inventory write-downs for the lower of cost and net realizable value); freight; distribution; shipping; and store occupancy costs. The Company defines merchandise margin as net sales less the cost of merchandise sold.


(2) Column does not add due to rounding

 


DICK’S SPORTING GOODS, INC. AND SUBSIDIARIES


CONSOLIDATED STATEMENTS OF INCOME – UNAUDITED


(In thousands, except per share data)


39 Weeks Ended


October 31,

2020


% of


Sales


November 2,

2019


% of


Sales (2)

Net sales

$

6,458,712

100.00

%

$

6,142,093

100.00

%

Cost of goods sold, including occupancy and
distribution costs (1)

4,460,336

69.06

4,320,571

70.34

GROSS PROFIT

1,998,376

30.94

1,821,522

29.66

Selling, general and administrative expenses

1,537,371

23.80

1,539,934

25.07

Pre-opening expenses

9,728

0.15

4,887

0.08

INCOME FROM OPERATIONS

451,277

6.99

276,701

4.50

(Gain) loss on sale of subsidiaries

(33,779)

(0.55)

Interest expense

35,496

0.55

12,909

0.21

Other (income) expense

(4,731)

(0.07)

(10,340)

(0.17)

INCOME BEFORE INCOME TAXES

420,512

6.51

307,911

5.01

Provision for income taxes

109,875

1.70

80,268

1.31

NET INCOME

$

310,637

4.81

%

$

227,643

3.71

%

EARNINGS PER COMMON SHARE:

Basic

$

3.69

$

2.57

Diluted

$

3.44

$

2.53

WEIGHTED AVERAGE COMMON SHARES
   OUTSTANDING:

Basic

84,095

88,671

Diluted

90,430

90,130


(1) Cost of goods sold includes: the cost of merchandise (inclusive of vendor allowances, inventory shrinkage and inventory write-downs for the lower of cost and net realizable value); freight; distribution; shipping; and store occupancy costs. The Company defines merchandise margin as net sales less the cost of merchandise sold.


(2) Column does not add due to rounding

 


DICK’S SPORTING GOODS, INC. AND SUBSIDIARIES


CONSOLIDATED BALANCE SHEETS – UNAUDITED


(In thousands)


October 31,

2020


November 2,

2019


February 1,

2020


ASSETS

CURRENT ASSETS:

Cash and cash equivalents

$

1,059,994

$

87,622

$

69,334

Accounts receivable, net

77,212

70,463

53,173

Income taxes receivable

5,453

17,122

5,762

Inventories, net

2,319,992

2,573,250

2,202,275

Prepaid expenses and other current assets

82,648

128,458

79,472

Total current assets

3,545,299

2,876,915

2,410,016

Property and equipment, net

1,336,676

1,436,975

1,415,728

Operating lease assets

2,177,006

2,378,399

2,313,846

Intangible assets, net

91,585

123,855

94,768

Goodwill

245,857

245,857

245,857

Deferred income taxes

27,717

16,033

14,412

Other assets

141,350

128,965

133,933


TOTAL ASSETS

$

7,565,490

$

7,206,999

$

6,628,560


LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:

Accounts payable

$

1,394,904

$

1,097,564

$

1,001,589

Accrued expenses

449,304

379,774

415,501

Operating lease liabilities

474,803

417,912

422,970

Income taxes payable

24,805

2,519

10,455

Deferred revenue and other liabilities

193,956

183,876

225,959

Total current liabilities

2,537,772

2,081,645

2,076,474

LONG-TERM LIABILITIES:

Revolving credit borrowings

719,300

224,100

 Convertible senior notes due 2025

411,256

Long-term operating lease liabilities

2,310,318

2,509,866

2,453,346

Deferred income taxes

8,530

9,187

Other long-term liabilities

184,505

178,756

133,855

Total long-term liabilities

2,906,079

3,416,452

2,820,488

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ EQUITY:

Common stock

608

597

593

Class B common stock

239

243

243

Additional paid-in capital

1,415,909

1,240,864

1,253,867

Retained earnings

2,873,263

2,599,495

2,645,281

 Accumulated other comprehensive loss

(114)

(116)

(120)

Treasury stock, at cost

(2,168,266)

(2,132,181)

(2,168,266)

Total stockholders’ equity

2,121,639

1,708,902

1,731,598


TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

7,565,490

$

7,206,999

$

6,628,560

 


DICK’S SPORTING GOODS, INC. AND SUBSIDIARIES


CONSOLIDATED STATEMENTS OF CASH FLOWS – UNAUDITED


(In thousands)


39 Weeks Ended


October 31,

2020


November 2,

2019

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income

$

310,637

$

227,643

Adjustments to reconcile net income to net cash provided by (used in)
operating activities:

Depreciation, amortization, and other

239,666

244,163

Amortization of convertible notes discount and issuance costs

14,345

Non-cash lease costs

(1,199)

(43,011)

Deferred income taxes

(22,492)

(3,438)

Stock-based compensation

35,631

31,742

Gain on sale of subsidiaries

(33,779)

Changes in assets and liabilities:

Accounts receivable

(12,099)

(22,636)

Inventories

(121,435)

(758,016)

Prepaid expenses and other assets

(384)

3,822

Accounts payable

381,383

168,259

Accrued expenses

30,035

11,424

Income taxes payable / receivable

14,659

(28,610)

Deferred construction allowances

42,314

25,598

Deferred revenue and other liabilities

6,454

(35,936)

Net cash provided by (used in) operating activities

917,515

(212,775)

CASH FLOWS FROM INVESTING ACTIVITIES:

 Capital expenditures

(156,444)

(165,703)

        Proceeds from sale of subsidiaries, net of cash sold

40,387

        Proceeds from sale of other assets

4,103

       Deposits and purchases of other assets

(96)

(1,000)

Net cash used in investing activities

(156,540)

(122,213)

CASH FLOWS FROM FINANCING ACTIVITIES:

Revolving credit borrowings

1,291,700

1,778,750

Revolving credit repayments

(1,515,800)

(1,059,450)

Proceeds from issuance of convertible notes

575,000

Payments for purchase of bond hedges

(161,057)

Proceeds from issuance of warrants

105,225

Transaction costs paid in connection with convertible notes issuance

(17,396)

          Payments on other long-term debt and finance lease obligations

(612)

(3,965)

          Proceeds from exercise of stock options

25,472

1,160

Minimum tax withholding requirements

(3,911)

(6,320)

Cash paid for treasury stock

(366,148)

Cash dividends paid to stockholders

(80,874)

(74,540)

Increase in bank overdraft

11,932

39,466

Net cash provided by financing activities

229,679

308,953

EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH
EQUIVALENTS

6

4

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

990,660

(26,031)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

69,334

113,653

CASH AND CASH EQUIVALENTS, END OF PERIOD

$

1,059,994

$

87,622


Store Count and Square Footage

The stores that opened during the third quarter of 2020 are as follows:


Store


Market


Concept

Cape Cod, MA

Cape Cod

DICK’S Sporting Goods

Cumberland, GA

Atlanta

DICK’S Sporting Goods

Midland, TX

Midland

DICK’S Sporting Goods

San Antonio, TX

San Antonio

DICK’S Sporting Goods

Annapolis, MD

Baltimore

DICK’S Sporting Goods

Copperfield, TX

Houston

DICK’S Sporting Goods

Myrtle Beach, SC

Myrtle Beach

Golf Galaxy

Cumberland, GA

Atlanta

Golf Galaxy

Canton, OH

Canton / Akron

Golf Galaxy

Monroeville, PA

Pittsburgh

Outlet Store

Tempe, AZ

Phoenix

Outlet Store

The following represents a reconciliation of beginning and ending stores and square footage for the periods indicated:

Store Count:


Fiscal 2020


Fiscal 2019


DICK’S Sporting
Goods


Specialty
Concept Stores


(1)


Total


DICK’S Sporting
Goods


Specialty
Concept Stores


(1)


Total

Beginning stores

726

124

850

729

130

859

Q1 New stores

1

2

3

1

1

Q2 New stores

3

3

2

2

4

Q3 New stores

6

5

11

6

1

7

Closed stores

1

5

6

4

9

13

Ending stores

732

129

861

733

125

858

Relocated stores

12

3

15

3

2

5

Square Footage:

(in millions)


DICK’S Sporting
Goods


Specialty Concept
Stores


(1)


Total
(2)

Q1 2019

38.6

3.7

42.2

Q2 2019

38.6

3.7

42.3

Q3 2019

38.8

3.4

42.2

Q4 2019

38.5

3.4

41.8

Q1 2020

38.4

3.4

41.8

Q2 2020

38.4

3.5

41.9

Q3 2020

38.7

3.6

42.3


(1)   

Includes the Company’s Golf Galaxy and Field & Stream stores, as well as the Company’s outlet stores. In some markets the Company operates DICK’S Sporting Goods stores adjacent to its specialty concept stores on the same property with a pass-through for customers. The Company refers to this format as a “combo store” and includes combo store openings within both the DICK’S Sporting Goods and specialty concept store reconciliations, as applicable. As of October 31, 2020, the Company operated 30 combo stores.


(2)   

Column may not add due to rounding.

 


DICK’S SPORTING GOODS, INC.


GAAP to NON-GAAP RECONCILIATIONS – UNAUDITED


(in thousands, except per share amounts)



Non-GAAP Net Income and Earnings Per Share Reconciliations


13 Weeks Ended October 31, 2020


Income from
operations


Interest
expense


Income before
income taxes


Net



income (2)


Diluted
shares
outstanding
during
period


Earnings
per
diluted
share

GAAP Basis

$

246,093

$

12,769

$

237,070

$

177,216

96,571

$

1.84


% of Net Sales


10.20


%


0.53


%


9.83


%


7.35


%

Convertible senior notes (1)

(6,683)

6,683

4,945

(5,976)

Non-GAAP Basis

$

246,093

$

6,086

$

243,753

$

182,161

90,595

$

2.01


% of Net Sales


10.20


%


0.25


%


10.11


%


7.55


%


(1) 

Amortization of the non-cash debt discount on the Company’s convertible senior notes and diluted shares that will be offset at settlement by shares delivered from the convertible note hedge purchased by the Company.


(2) 

The provision for income taxes for Non-GAAP adjustments was calculated at 26%, which approximates the Company’s blended tax rate.

 


39 Weeks Ended October 31, 2020


Income from
operations


Interest
expense


Income
before
income taxes


Net


income (2)


Diluted
shares
outstanding
during
period


Earnings
per
diluted
share

GAAP Basis

$

451,277

$

35,496

$

420,512

$

310,637

90,430

$

3.44


% of Net Sales


6.99


%


0.55


%


6.51


%


4.81


%

Convertible senior notes (1)

(14,345)

14,345

10,615

(2,365)

Non-GAAP Basis

$

451,277

$

21,151

$

434,857

$

321,252

88,065

$

3.65


% of Net Sales


6.99


%


0.33


%


6.73


%


4.97


%


(1) 

Amortization of the non-cash debt discount on the Company’s convertible senior notes and diluted shares that will be offset at settlement by shares delivered from the convertible note hedge purchased by the Company. This amount includes $1.1 million of amortization recognized in the fiscal quarter ended May 2, 2020.


(2) 

The provision for income taxes for Non-GAAP adjustments was calculated at 26%, which approximates the Company’s blended tax rate.

 


13 Weeks Ended November 2, 2019


Selling, general
and
administrative
expenses


Income from
operations


Gain on sale of
subsidiaries


Income
before
income
taxes


Net


income (4)


Earnings
per
diluted
share

GAAP Basis

$

531,704

$

45,625

$

(33,779)

$

77,146

$

57,584

$

0.66


% of Net Sales


27.10


%


2.33


%


(1.72)


%


3.93


%


2.93


%

Gain on sale of subsidiaries (1)

33,779

(33,779)

(24,996)

Field & Stream store closing costs (2)

(8,938)

8,938

8,938

6,614

Non-cash asset impairment (3)

(7,630)

7,630

7,630

5,646

Non-GAAP Basis

$

515,136

$

62,193

$

$

59,935

$

44,848

$

0.52


% of Net Sales


26.25


%


3.17


%




%


3.05


%


2.29


%


(1) 

Gain on sale of Blue Sombrero and Affinity Sports subsidiaries.


(2) 

Charge related to the Company’s exit from eight Field & Stream stores, which were subleased to Sportsman’s Warehouse.


(3) 

Non-cash impairment charge to reduce the carrying value of a corporate aircraft held for sale to its fair market value.


(4) 

The provision for income taxes for Non-GAAP adjustments was calculated at 26%, which approximated the Company’s blended tax rate.

 


39 Weeks Ended November 2, 2019


Selling, general
and
administrative
expenses


Income from
operations


Gain on sale
of
subsidiaries


Income
before
income
taxes


Net
income
(5)


Earnings
per
diluted
share

GAAP Basis

$

1,539,934

$

276,701

$

(33,779)

$

307,911

$

227,643

$

2.53


% of Net Sales


25.07


%


4.50


%


(0.55)


%


5.01


%


3.71


%

Gain on sale of subsidiaries (1)

33,779

(33,779)

(24,996)

Field & Stream store closing costs (2)

(8,938)

8,938

8,938

6,614

Non-cash asset impairment (3)

(15,253)

15,253

15,253

11,287

Litigation contingency settlement (4)

6,411

(6,411)

(6,411)

(4,744)

Non-GAAP Basis

$

1,522,154

$

294,481

$

$

291,912

$

215,804

$

2.39


% of Net Sales


24.78


%


4.79


%




%


4.75


%


3.51


%


(1) 

Gain on sale of Blue Sombrero and Affinity Sports subsidiaries.


(2) 

Charge related to the Company’s exit from eight Field & Stream stores, which were subleased to Sportsman’s Warehouse.


(3) 

Non-cash impairment charge to reduce the carrying value of a corporate aircraft held for sale to its fair market value.


(4) 

Favorable settlement of a previously accrued litigation contingency.


(5) 

The provision for income taxes for Non-GAAP adjustments was calculated at 26%, which approximated the Company’s blended tax rate.


Reconciliation of Gross Capital Expenditures to Net Capital Expenditures

The following table represents a reconciliation of the Company’s gross capital expenditures to its capital expenditures, net of tenant allowances.


39 Weeks Ended


October 31,

2020


November 2,

2019


(dollars in thousands)

Gross capital expenditures

$

(156,444)

$

(165,703)

Proceeds from sale-leaseback transactions

Deferred construction allowances

42,314

25,598

Construction allowance receipts

Net capital expenditures

$

(114,130)

$

(140,105)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/dicks-sporting-goods-reports-third-quarter-results-delivers-record-setting-23-2-increase-in-same-store-sales-301179382.html

SOURCE DICK’S Sporting Goods, Inc.

Quest Diagnostics Earns Gold Status in American Heart Association’s 2020 Workplace Health Achievement Index

Award follows a series of other recognitions for HealthyQuest, the company’s employer population health program

PR Newswire

SECAUCUS, N.J., Nov. 24, 2020 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has achieved Gold status in the American Heart Association’s 2020 Workplace Health Achievement Index, ranking the company’s workplace health initiative among the best in the nation. 2020 marks the third year in a row that Quest has earned this distinction, which comes on the heels of recognitions for the company’s HealthyQuest employee population health program, including the C. Everett Koop and National Business Group on Health awards.

The Quest Diagnostics employee population health strategy is centered on the Institute for Healthcare Improvement’s “Triple Aim” approach—enhancing the experience of care, improving population health, and reducing per capita healthcare costs. Through the HealthyQuest program, the company provides more than 60,000 employees and family members with best-in-class programs to improve their health and save money.

“The COVID-19 pandemic has shined a light on overall health and the growing divide of health equity, said Nancy Brown, CEO of the American Heart Association. “I am inspired by organizations like Quest Diagnostics who are doubling down to prioritize employee health through flexible and engaging programs that put health and well-being at the center, especially during these trying times.”

“Given COVID-19, good employee health and well-being is more important than ever,” said Steve Rusckowski, Chairman, CEO and President, Quest Diagnostics. “We’re thrilled that the AHA has recognized the value of our strategy, which uses a targeted, data-driven approach to help colleagues and their families access medical care and emotional support during this difficult time. Through our Employer Population Health services, we also empower other organizations to implement employee health strategies based on our model, for better care, costs and outcomes.”

Quest Diagnostics provides a range of employer population health services to other organizations, including COVID-19 return to work services and, through a relationship with Catapult, clinical-grade virtual preventive care services.

This year alone, multiple organizations have recognized Quest Diagnostics for its employee population health programs. In addition to the AHA, Quest was the only 2020 recipient of The Health Project’s C. Everett Koop National Health Award, and was recognized by the National Business Group on Health. Previous recognitions for Quest’s program include 10 years of accreditation by the CEO Roundtable on Cancer.

Supporting Employees During the COVID-19 Pandemic
Based on early insights revealing the need to engage employees with greater health risks, Quest Diagnostics has strategically implemented programs that meet employee needs since the beginning of the COVID-19 pandemic. Programs support the physical, emotional, and social needs of employees and range from virtual care (telehealth), diabetes prevention and weight management, mental health screening and support, and connections to care.

About Quest Diagnostics Employer Population Health

Quest Diagnostics Employer Population Health is the leader in employee population health management and screening solutions designed to improve outcomes and costs for employers. With nationwide lab access and insights from clinical data, Quest Diagnostics provides health screenings and related population health solutions to identify chronic disease risks, connect employees to needed in-network care, and empower better health. Quest Diagnostics also provides COVID-19 Return to Work Services to foster safer workplace environments during the COVID-19 pandemic. Quest Diagnostics has won countless awards for its employer population health programs, including the prestigious C. Everett Koop Award for 2020. For more information, visit www.QuestForHealth.com

About Quest Diagnostics 
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com

About the American Heart Association

The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-earns-gold-status-in-american-heart-associations-2020-workplace-health-achievement-index-301179087.html

SOURCE Quest Diagnostics

Pacira BioSciences to Present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference

PARSIPPANY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) — PaciraBioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference at 11:30 AM ET on Tuesday, December 1, 2020. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About
Pacira         

Pacira BioSciences, Inc. (NASDAQ: PCRX) is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Company Contact:

Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
[email protected]



36Kr Holdings Inc. to Report Third Quarter 2020 Financial Results on Monday, November 30, 2020

Earnings Call Scheduled for 8:00 a.m. ET on November 30, 2020

BEIJING, Nov. 24, 2020 (GLOBE NEWSWIRE) — 36Kr Holdings Inc. (“36Kr” or the “Company” or “We”) (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced that it will report its third quarter 2020 unaudited financial results, on Monday, November 30, 2020, before the open of U.S. markets.

The Company’s management will host an earnings conference call at 8:00 AM U.S. Eastern Time on November 30, 2020 (9:00 PM Beijing/Hong Kong Time on November 30, 2020). Details for the conference call are as follows:

Event Title: 36Kr Holdings Inc. Third Quarter 2020 Earnings Conference Call
Conference ID: 8996858
Registration Link: http://apac.directeventreg.com/registration/event/8996858

All participants must use the link provided above to complete the online registration process at least 20 minutes in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in number, Direct Event passcode, and a unique registrant ID, which will be used to join the conference call.

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at http://ir.36kr.com.

A replay of the conference call will be accessible approximately two hours after the conclusion of the live call until December 7, 2020, by dialing the following telephone numbers:

United States: +1-855-452-5696
International: +61-2-8199-0299
Hong Kong, China: 800-963-117
Mainland China: 400-632-2162
Replay Access Code: 8996858

About 36Kr Holdings Inc.

36Kr Holdings Inc. is a prominent brand and a pioneering platform dedicated to serving New Economy participants in China with the mission of empowering New Economy participants to achieve more. The Company started its business with high-quality New Economy-focused content offerings, covering a variety of industries in China’s New Economy with diverse distribution channels. Leveraging traffic brought by high-quality content, the Company has expanded its offerings to business services, including online advertising services, enterprise value-added services and subscription services to address the evolving needs of New Economy companies and upgrading needs of traditional companies. The Company is supported by comprehensive database and strong data analytics capabilities. Through diverse service offerings and the significant brand influence, the Company is well-positioned to continuously capture the high growth potentials of China’s New Economy.

For more information, please visit: http://ir.36kr.com.

For investor and media inquiries, please contact:

In China:

36Kr Holdings Inc.
Investor Relations
Tel: +86 (10) 5825-4188
E-mail: [email protected]

The Piacente Group, Inc.
Jenny Cai
Tel: +86 (10) 6508-0677
E-mail: [email protected]

In the United States:

The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: [email protected]



Strongbridge Biopharma plc Announces Publication of Secondary Endpoints Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in the Journal, Pituitary

~ RECORLEV™ (levoketoconazole) Treatment Resulted in Significantly Improved Clinician-Assessed Signs and Symptoms and Patient-Reported Outcomes of Cushing’s Syndrome ~

DUBLIN, Ireland and TREVOSE, Pa., Nov. 24, 2020 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that secondary endpoint results from the Phase 3 SONICS study of RECORLEV™ (levoketoconazole) for the potential treatment of endogenous Cushing’s syndrome were published online in advance of print publication in the peer-reviewed journal, Pituitary, the official publication of the Pituitary Society and the Growth Hormone Research Society.

“People with Cushing’s syndrome often experience a variety of problematic signs, symptoms, and comorbidities related to excess cortisol, testosterone or both,” said Fredric Cohen, M.D., chief medical officer of Strongbridge Biopharma. “The SONICS study provided important evidence that RECORLEV treatment was associated with durable improvements in several of the more common and bothersome signs and symptoms of the syndrome, including those that most commonly affect women, such as hirsutism and acne, which are related to increases in testosterone produced by the adrenal glands.”

The manuscript, entitled “Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome,” includes analyses demonstrating that treatment with RECORLEV led to significant improvements in Cushing’s syndrome signs and symptoms, patient-reported quality of life (QoL) outcomes, depression symptoms, and testosterone levels.

  • Significant mean improvements from baseline were noted at end of the Maintenance phase (Month 6) for acne, hirsutism (females only), and peripheral edema.
  • These improvements were observed as early as Day 1 of Maintenance for hirsutism, the end of Month 1 of Maintenance for acne, and Month 4 of Maintenance for peripheral edema.
  • By Month 3 of Maintenance, significant mean improvements in patient-reported QoL outcomes were observed and by Month 6, symptoms of depression had improved.
  • A reduction in mean free-testosterone in women, consistent with improvements in clinical signs of hyperandrogenism was observed, and a modest increase in mean free-testosterone in men was observed.
  • RECORLEV was generally well-tolerated; the most commonly reported adverse events during the dose-titration and maintenance phases were nausea (32%) and headache (28%).

The full manuscript can be accessed online at: https://www.strongbridgebio.com/therapeutic-focus/key-publications-posters/related-investigational-agent-recorlev/#heading_4

About Cushing’s Syndrome

Endogenous Cushing’s syndrome is a rare, serious and potentially lethal endocrine disease caused by chronic elevated cortisol exposure – often the result of a benign tumor of the pituitary gland. This benign tumor tells the body to overproduce high levels of cortisol for a sustained period of time, and this often results in undesirable physical changes. The disease is most common among adults between the ages of 30 to 50, and it affects women three times more often than men. Women with Cushing’s syndrome may experience a variety of health issues including menstrual problems, difficulty becoming pregnant, excess male hormones (androgens), primarily testosterone which can cause hirsutism (growth of coarse body hair in a male pattern), oily skin, and acne. Additionally, the internal manifestations of the disease are potentially life threatening. These include metabolic changes such as high blood sugar, or diabetes, high blood pressure, high cholesterol, fragility of various tissues including blood vessels, skin, muscle and bone, and psychologic disturbances such as depression, anxiety and insomnia. Untreated, the five-year survival rate is only approximately 50 percent.

About
 
the
 
SONICS
 
Study

SONICS is an open-label, Phase 3 study of RECORLEV as a treatment for endogenous Cushing’s syndrome that enrolled 94 patients at centers in North America, Europe and the Middle East. Following a screening phase, SONICS has three treatment phases:

(1) Dose Titration Phase: Patients started RECORLEV at 150 mg twice daily (300 mg total daily dose) and titrated in 150 mg increments with the goal of achieving a therapeutic dose – a dose resulting in mUFC normalization – at which point titration was stopped; (2) Maintenance Phase: The dose was fixed and should not have been changed other than for safety reasons or loss of efficacy. At the end of the six-month maintenance phase, the mUFC response rate was measured; and (3) Extended Evaluation Phase: Patients continued on RECORLEV for another six months to evaluate long-term safety and tolerability and explore efficacy durability.

About RECORLEV

RECORLEV® (levoketoconazole) is an investigational cortisol synthesis inhibitor in development for the treatment of patients with endogenous Cushing’s syndrome, a rare but serious and potentially lethal endocrine disease caused by chronic elevated cortisol exposure. RECORLEV is the pure 2S,4R enantiomer of ketoconazole, a steroidogenesis inhibitor. RECORLEV has demonstrated in two successful Phase 3 studies to significantly suppress serum cortisol and has the potential to be a next-generation cortisol inhibitor.

The Phase 3 program for RECORLEV includes SONICS and LOGICS: two multinational studies designed to evaluate the safety and efficacy of RECORLEV when used to treat endogenous Cushing’s syndrome. The SONICS study met its primary and secondary endpoints, demonstrating a statistically significant normalization rate of urinary free cortisol at six months. The LOGICS study, which met its primary endpoint, is a double-blind, placebo-controlled randomized-withdrawal study of RECORLEV that is designed to supplement the long-term efficacy and safety information supplied by SONICS. The ongoing long-term open label OPTICS study will gather further useful information related to the long-term use of RECORLEV.

RECORLEV has received orphan drug designation from the FDA and the European Medicines Agency for the treatment of endogenous Cushing’s syndrome.

About Strongbridge Biopharma

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. The words “anticipate,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will,” “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements of historical facts, contained in this press release, are forward-looking statements, including statements related to the
secondary endpoint data from the SONICS
study
, the potential advantages of RECORLEV,  Strongbridge’s strategy, plans, outcomes of product development efforts and objectives of management for future operations. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in such statement, including risks and uncertainties associated with clinical development and the regulatory approval process, the reproducibility of any reported results showing the benefits of RECORLEV, the adoption of RECORLEV by physicians, if approved, as treatment for any disease and the emergence of unexpected adverse events following regulatory approval and use of the product by patients.  Additional risks and uncertainties relating to Strongbridge and its business can be found under the heading “Risk Factors” in Strongbridge’s Annual Report on Form 10-K for the year ended December 31, 2019 and
its
subsequent
Quarterly Reports on Form 10-Q, as well as its other
filings with the SEC. These forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. The forward-looking statements contained in this press release are made as of the date of this press release, and Strongbridge Biopharma does not assume any obligation to update any forward-looking statements except as required by applicable law.

Contacts:

Corporate and Media Relations

Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
[email protected]

Investor Relations

Solebury Trout
Mike Biega
+1 617-221-9660
[email protected] 



Dollar Tree, Inc. Reports Results for the Third Quarter Fiscal 2020

Dollar Tree, Inc. Reports Results for the Third Quarter Fiscal 2020

~ Diluted Earnings per Share Increased 28.7% to $1.39 vs. $1.08 ~

~ Consolidated Net Sales Increased 7.5% to $6.18 Billion ~

~ Same-Store Sales: Enterprise +5.1%; Family Dollar +6.4%; Dollar Tree +4.0% ~

~ Dollar Tree Segment Operating Margin Improved 50 bps to 12.7% ~

~ Expanding Dollar Tree Plus! Offering to Approximately 500 Stores Beginning Spring 2021 ~

CHESAPEAKE, Va.–(BUSINESS WIRE)–
Dollar Tree, Inc. (NASDAQ: DLTR) today reported financial results for its third quarter ended October 31, 2020.

“I am incredibly proud of our team’s efforts to continue serving customers effectively, while driving operational improvements in both banners through this dynamic retail environment,” stated Mike Witynski, President and Chief Executive Officer. “Dollar Tree delivered its strongest same-store sales performance in the past ten quarters, along with a 50 basis point improvement in operating margin. At Family Dollar, the improvement continues as the team delivered a 6.4% comparable store sales increase, a 230 basis point improvement in gross profit margin and a 250 basis point improvement in operating margin.”

Third Quarter Results

Consolidated net sales increased 7.5% to $6.18 billion from $5.75 billion in the prior year’s third quarter. Enterprise same-store sales increased 5.1%. Same-store sales for Family Dollar increased 6.4%. Dollar Tree same-store sales increased 4.0%.

Gross profit increased 12.9% to $1.92 billion in the quarter compared to the prior year’s third quarter. Gross margin increased 150 basis points to 31.2%, compared to 29.7% in the prior year’s quarter. The increase in gross margin was driven by improved merchandise costs including freight, leverage on occupancy costs from stronger same-store sales, improved shrink results and reduced markdowns, partially offset by higher distribution costs, which included $10.9 million in COVID-19-related payroll costs.

Selling, general and administrative expenses were 23.7% of net sales, compared to 23.5% of net sales in the prior year’s third quarter. The increase was driven by COVID-19 costs of $35.3 million, or 57 basis points, related to frontline associate wage premiums, field management bonuses and store cleaning/PPE supplies.

Operating income for the quarter improved 29.9% to $465.5 million, compared with $358.4 million in the same period last year and operating income margin was 7.5% in the current quarter, compared to 6.2% in last year’s quarter. The third quarter of 2020 included total incremental operating costs of $46.3 million, or $0.15 per diluted share, for COVID-19-related expenses. These incremental costs by segment were $28.6 million for Dollar Tree, $17.4 million for Family Dollar and $0.3 million for Corporate, Support and Other.

Net income was $330.0 million in the third quarter and diluted earnings per share for the quarter increased 28.7% to $1.39, compared to $1.08 per share in the prior year’s quarter.

The Company repurchased 2,154,304 shares during the quarter for $200 million. The Company has $600 million remaining on its share repurchase authorization.

The Company opened 143 new stores, expanded or relocated 34 stores, and closed 16 stores. Additionally, the Company completed 371 renovations to the Family Dollar H2 format. Retail selling square footage at quarter end was approximately 124.3 million square feet.

First Nine Months Results

Consolidated net sales increased 8.4% to $18.74 billion from $17.30 billion in the same period last year. Enterprise same-store sales increased 6.5% on a constant currency basis (or 6.4% when adjusted to include the impact of Canadian currency fluctuations.), when compared to the prior year period. Same-store sales for Family Dollar increased 11.2%. Dollar Tree same-store sales increased 2.1%.

Gross profit for the first nine months increased 10.9% to $5.64 billion. As a percentage of net sales, gross margin improved 70 basis points to 30.1%, compared to 29.4% in the prior year period. The current year includes $28.7 million, or 0.2% of net sales, in COVID-19 costs.

Selling, general and administrative expenses were 23.7% of net sales, compared to 23.5% of net sales in the first nine months of 2019. The current year includes $225.6 million, or 1.2% of net sales, in COVID-19 costs.

Operating income for the period improved 19.1% to $1.21 billion. Operating income margin increased 50 basis points to 6.4% of net sales in the current year period from 5.9% of net sales in the prior year. The first nine months of 2020 included incremental operating costs of $254.3 million, or $0.82 per diluted share, for COVID-19-related expenses, which included wage premiums paid to hourly store and distribution center associates, and safety and sanitization supplies. These incremental costs by segment were $147.4 million for Dollar Tree, $104.9 million for Family Dollar and $2.0 million for Corporate, Support and Other.

Net income compared to the prior year period improved 19.2% to $839.1 million and diluted earnings per share increased 19.7% to $3.53 compared to $2.95 in the prior year period.

Leveraging the Power of Both Brands

The combination of Dollar Tree and Family Dollar provides the Company more opportunities to better serve more customers in more ways, and in more locations across the country.

In recent years, the Company has made significant progress in optimizing its portfolio of stores through new store openings, renovations, re-banners and closings. The H2 renovation program at Family Dollar continues to be a key component of the momentum in the turnaround. The H2 stores, on average, continue to comp at a 10%+ lift vs. non-renovated stores in their first year. Customers are responding favorably to the new categories and new price points. Sell through on seasonal items has been exceptional. There is continued opportunity to renovate older Family Dollar stores. As of October 31, 2020, the Company has approximately 2,240 Family Dollar stores in the H2 format. The Company currently plans to renovate approximately 1,250 Family Dollar stores in 2021.

Additionally, for more than a year, Dollar Tree has tested a multi-price initiative referred to as Dollar Tree Plus! In mid-2019, the Company began testing multi-price assortments in more than 100 stores in southwestern markets. Major modifications, based on learnings, have included: transitioning the offering from consumable products to primarily discretionary items; reengineering the display elements and signage to drive awareness and excitement in stores; focusing on the $1, $3 and $5 price points; and increasing the offerings above the $1 price point. The Company will be expanding this initiative into a total of approximately 500 stores beginning in the spring of 2021.

Since acquiring Family Dollar, the Company has produced strong cash flow from operations, paid down debt aggressively, repurchased $400 million in shares, mitigated the majority of impacts from tariffs proactively, consolidated its two store support centers and realigned leadership under one executive team. These actions enhance the Company’s ability and flexibility to better leverage the two powerful brands to drive improved productivity, efficiencies and returns.

“The team has accomplished a great deal to get us to this stage. With one consolidated store support center; a strong balance sheet; an aligned, energized and focused leadership team; and a full staff of talented retailers, we believe we have the ability to better serve customers across North America,” Witynski added. “We have a unique and transformational opportunity to leverage the power of our two brands, through flexible store formats designed to drive improved operational performance.”

Update on Company Outlook, Initiatives and Liquidity

Due to continued volatility and uncertainty related to the COVID-19 pandemic, as well as a lack of visibility into government stimulus initiatives, the Company is not providing updated guidance at this time.

The Company now expects the completion of approximately 480 new store openings and 750 Family Dollar H2 store renovations in fiscal 2020.

Capital expenditures for fiscal 2020 are expected to be approximately $1.0 billion.

The Company ended the quarter with $1.12 billion in cash on its balance sheet. The Company paid down the remaining $500 million on its revolving line of credit during the third quarter. Additionally, the Company plans to pay off a $300 million legacy Family Dollar note due in February 2021.

“It’s an exciting time at Dollar Tree. We are just over three weeks into our important fourth quarter and we are off to a very good start, with same-store sales at both banners currently tracking above reported third quarter levels. Our focus will continue to be on opening new stores, refining our store formats and upgrading our assortments to drive improved store productivity, increasing operating efficiencies, generating free cash flow and buying back shares,” Witynski concluded. “These efforts are designed to deliver continued value to our long-term shareholders.”

Conference Call Information

On Tuesday, November 24, 2020, the Company will host a conference call to discuss its earnings results at 9:00 a.m. Eastern Time. The telephone number for the call is 855-710-4184. A recorded version of the call will be available until midnight Monday, November 30, 2020, and may be accessed by dialing 888-203-1112. The access code is 2631833. A webcast of the call is accessible through Dollar Tree’s website and will remain online through Monday, November 30, 2020.

Dollar Tree, a Fortune 200 Company, operated 15,606 stores across 48 states and five Canadian provinces as of October 31, 2020. Stores operate under the brands of Dollar Tree, Family Dollar, and Dollar Tree Canada. To learn more about the Company, visit www.DollarTree.com.

A WARNING ABOUT FORWARD-LOOKING STATEMENTS: Our press release contains “forward-looking statements” as that term is used in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the fact that they address future events, developments or results and do not relate strictly to historical facts. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements include, without limitation, statements preceded by, followed by or including words such as “believe”, “anticipate”, “expect”, “intend”, “plan”, “view”, “target” or “estimate”, “may”, “will”, “should”, “predict”, “possible”, “potential”, “continue”, “strategy”,” and similar expressions. For example, our forward-looking statements include statements regarding our expectations regarding new store openings and capital expenditures for fiscal 2020; our plans and expectations concerning various store format initiatives, including Family Dollar H2 renovations; the expansion of our Dollar Tree Plus! initiative; our plan to pay off certain legacy Family Dollar debt; and our other plans, objectives, expectations (financial and otherwise) and intentions. These statements are subject to risks and uncertainties. For a discussion of the risks, uncertainties and assumptions that could affect our future events, developments or results, you should carefully review the “Risk Factors,” “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in our Annual Report on Form 10-K filed March 20, 2020, our Form 10-Q for the most recently ended fiscal quarter and other filings we make from time to time with the Securities and Exchange Commission. We are not obligated to release publicly any revisions to any forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this report and you should not expect us to do so.

DLTR-E

 
DOLLAR TREE, INC.
Condensed Consolidated Income Statements
(In millions, except per share data)
(Unaudited)
 
13 Weeks Ended 39 Weeks Ended
October 31, 2020 November 2, 2019 October 31, 2020 November 2, 2019
 
Net sales

$ 6,177.0

$ 5,746.2

$ 18,741.4

$ 17,295.5

 
Cost of sales

4,252.6

4,041.7

13,105.9

12,215.3

 
Gross profit

1,924.4

1,704.5

5,635.5

5,080.2

31.2%

29.7%

30.1%

29.4%

 
Selling, general and administrative expenses

1,458.9

1,346.1

4,429.2

4,067.4

23.7%

23.5%

23.7%

23.5%

 
Operating income

465.5

358.4

1,206.3

1,012.8

7.5%

6.2%

6.4%

5.9%

 
Interest expense, net

38.1

41.4

113.1

122.9

Other expense, net

0.1

0.1

0.8

0.7

 
Income before income taxes

427.3

316.9

1,092.4

889.2

6.9%

5.5%

5.8%

5.1%

 
Provision for income taxes

97.3

61.1

253.3

185.2

Income tax rate

22.8%

19.3%

23.2%

20.8%

 
Net income

$ 330.0

$ 255.8

$ 839.1

$ 704.0

5.3%

4.5%

4.5%

4.1%

 
Net earnings per share:
Basic

$ 1.39

$ 1.08

$ 3.54

$ 2.97

Weighted average number of shares

236.8

236.7

237.0

237.4

 
Diluted

$ 1.39

$ 1.08

$ 3.53

$ 2.95

Weighted average number of shares

237.9

237.5

237.8

238.3

 
 

DOLLAR TREE, INC.

Reconciliation of Non-GAAP Financial Measures

(In millions, except per share data)

(Unaudited)

From time-to-time, the Company’s financial results include certain financial measures not derived in accordance with generally accepted accounting principles (“GAAP”). Non-GAAP financial measures should not be used as a substitute for GAAP financial measures, or considered in isolation, for the purposes of analyzing operating performance, financial position or cash flows. However, the Company believes providing additional information in the form of non-GAAP measures that exclude the unusual, non-recurring expenses outlined below is beneficial to the users of its financial statements in evaluating the Company’s current operating results in relation to past periods. In addition, the Company’s debt covenants exclude the impact of certain unusual, non-recurring expenses. The Company has included a reconciliation of this information to the most comparable GAAP measures in the following tables.

On February 3, 2019, the Company adopted Financial Accounting Standards Board Accounting Standards Update No. 2016-02, “Leases (Topic 842)” and subsequent amendments (“ASC 842”) which requires lessees to recognize right-of-use assets on the balance sheet. The Company did not elect the hindsight practical expedient; therefore, the adoption also resulted in the recognition of an estimate of the embedded impairment of right-of-use assets as a reduction to Retained earnings. In March 2019, the Company announced a store optimization program which included the closing of up to 390 under-performing stores in 2019. Under ASC 842, the right-of-use assets must be amortized over the remaining operating terms which resulted in the acceleration of rent expense for the stores that the Company closed in 2019. The accelerated rent expense net of the rent foregone as a result of the embedded lease impairment was $6.7 million and this amount will be excluded in calculating the Company’s compliance with its debt covenants, which requires reporting in accordance with GAAP as of the date of the Credit Agreement.

 
Reconciliation of Adjusted Net Income:
39 Weeks Ended
October 31, 2020 November 2, 2019
Net income (GAAP)

$ 839.1

$ 704.0

Accelerated rent expense

6.7

Provision for income taxes on adjustment

(1.5)

Adjusted Net income (Non-GAAP)

$ 839.1

$ 709.2

 
 
Reconciliation of Adjusted EPS:
39 Weeks Ended
October 31, 2020 November 2, 2019
Diluted earnings per share (GAAP)

$ 3.53

$ 2.95

Adjustment, net of tax

0.03

Adjusted EPS (Non-GAAP)

$ 3.53

$ 2.98

 
DOLLAR TREE, INC.
Segment Information
(In millions, except store count)
(Unaudited)
 
13 Weeks Ended 39 Weeks Ended
October 31, 2020 November 2, 2019 October 31, 2020 November 2, 2019
 
Net sales:
Dollar Tree

$ 3,303.2

$ 3,074.3

$ 9,557.6

$ 8,991.4

Family Dollar

2,873.5

2,671.9

9,183.5

8,304.1

Corporate, support and Other (a)

0.3

0.3

Total net sales

$ 6,177.0

$ 5,746.2

$ 18,741.4

$ 17,295.5

 
Gross profit:
Dollar Tree

$ 1,154.2

34.9%

$ 1,050.5

34.2%

$ 3,206.8

33.6%

$ 3,070.8

34.2%

Family Dollar

769.9

26.8%

654.0

24.5%

2,428.4

26.4%

2,009.4

24.2%

Corporate, support and Other (a)

0.3

100.0%

0.0%

0.3

100.0%

0.0%

Total gross profit

$ 1,924.4

31.2%

$ 1,704.5

29.7%

$ 5,635.5

30.1%

$ 5,080.2

29.4%

 
Operating income (loss):
Dollar Tree

$ 417.9

12.7%

$ 374.6

12.2%

$ 1,006.5

10.5%

$ 1,105.9

12.3%

Family Dollar

131.4

4.6%

55.2

2.1%

472.0

5.1%

163.9

2.0%

Corporate, support and Other (a)

(83.8)

(1.4%)

(71.4)

(1.2%)

(272.2)

(1.5%)

(257.0)

(1.5%)

Total operating income

$ 465.5

7.5%

$ 358.4

6.2%

$ 1,206.3

6.4%

$ 1,012.8

5.9%

 
(a) Corporate, support and Other revenue consists of rental income from our Summit Pointe property.
13 Weeks Ended 39 Weeks Ended
October 31, 2020 November 2, 2019 October 31, 2020 November 2, 2019
Dollar
Tree
Family
Dollar
Total Dollar
Tree
Family
Dollar
Total Dollar
Tree
Family
Dollar
Total Dollar
Tree
Family
Dollar
Total
Store Count:
Beginning

7,652

7,827

15,479

7,306

7,809

15,115

7,505

7,783

15,288

7,001

8,236

15,237

New stores

95

48

143

114

51

165

262

111

373

286

120

406

Re-bannered stores (b)

39

(15)

24

(3)

4

1

190

(199)

(9)

Closings

(6)

(10)

(16)

(12)

(30)

(42)

(23)

(33)

(56)

(30)

(342)

(372)

Ending

7,741

7,865

15,606

7,447

7,815

15,262

7,741

7,865

15,606

7,447

7,815

15,262

Selling Square Footage (in millions)

66.7

57.6

124.3

64.1

56.9

121.0

66.7

57.6

124.3

64.1

56.9

121.0

Growth Rate (Square Footage)

4.1%

1.2%

2.7%

7.6%

(5.0%)

1.3%

4.1%

1.2%

2.7%

7.6%

(5.0%)

1.3%

 
(b) Stores are included as re-banners when they close or open, respectively.
 
DOLLAR TREE, INC.
Condensed Consolidated Balance Sheets
(In millions)
(Unaudited)
 
October 31, February 1, November 2,

2020

2020

2019

 
 
Cash and cash equivalents

$ 1,118.3

$ 539.2

$ 433.7

Merchandise inventories

3,792.3

3,522.0

3,882.9

Other current assets

260.4

208.2

255.7

Total current assets

5,171.0

4,269.4

4,572.3

 
Property, plant and equipment, net

4,095.6

3,881.8

3,810.7

Restricted cash

46.9

46.8

46.6

Operating lease right-of-use assets

6,185.1

6,225.0

5,864.6

Goodwill

1,983.1

1,983.3

2,296.5

Trade name intangible asset

3,100.0

3,100.0

3,100.0

Deferred tax asset

23.3

24.4

Other assets

47.2

43.9

51.4

 
Total assets

$ 20,652.2

$ 19,574.6

$ 19,742.1

 
 
Current portion of long-term debt

$ 300.0

$ 250.0

$ 750.0

Current portion of operating lease liabilities

1,296.5

1,279.3

1,202.6

Accounts payable

1,587.2

1,336.5

1,473.1

Income taxes payable

62.7

Other current liabilities

858.6

618.0

754.0

Total current liabilities

4,042.3

3,546.5

4,179.7

 
Long-term debt, net, excluding current portion

3,225.3

3,522.2

3,520.2

Operating lease liabilities, long-term

4,962.1

4,979.5

4,636.0

Deferred income taxes, net

1,043.1

984.7

1,001.5

Income taxes payable, long-term

31.0

28.9

29.7

Other liabilities

387.3

258.0

253.7

 
Total liabilities

13,691.1

13,319.8

13,620.8

 
Shareholders’ equity

6,961.1

6,254.8

6,121.3

 
Total liabilities and shareholders’ equity

$ 20,652.2

$ 19,574.6

$ 19,742.1

 

The February 1, 2020 information was derived from the audited consolidated financial statements as of that date.

 
DOLLAR TREE, INC.
Condensed Consolidated Statements of Cash Flows
(In millions)
(Unaudited)
39 Weeks Ended
October 31, November 2,

2020

2019

 
 
Cash flows from operating activities:
Net income

$ 839.1

$ 704.0

Adjustments to reconcile net income to net cash provided by
operating activities:
Depreciation and amortization

503.7

466.3

Provision for deferred income taxes

59.4

50.3

Stock-based compensation expense

70.5

52.5

Amortization of debt discount and debt-issuance costs

3.1

4.9

Other non-cash adjustments to net income

7.4

24.2

Changes in operating assets and liabilities

250.5

(287.7)

Total adjustments

894.6

310.5

Net cash provided by operating activities

1,733.7

1,014.5

 
Cash flows from investing activities:
Capital expenditures

(707.0)

(782.3)

Proceeds from governmental grant

16.5

Payments for fixed asset disposition

(0.5)

(2.9)

Net cash used in investing activities

(707.5)

(768.7)

 
Cash flows from financing activities:
Principal payments for long-term debt

(250.0)

Proceeds from revolving credit facility

750.0

Repayments of revolving credit facility

(750.0)

Proceeds from stock issued pursuant to stock-based compensation plans

14.3

12.3

Cash paid for taxes on exercises/vesting of stock-based compensation

(16.8)

(24.3)

Payments for repurchase of stock

(194.2)

(200.0)

Net cash used in financing activities

(446.7)

(212.0)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(0.3)

(0.2)

Net increase in cash, cash equivalents and restricted cash

579.2

33.6

Cash, cash equivalents and restricted cash at beginning of period

586.0

446.7

Cash, cash equivalents and restricted cash at end of period

$ 1,165.2

$ 480.3

 

 

Dollar Tree, Inc.

Randy Guiler, 757-321-5284

Vice President, Investor Relations

www.DollarTree.com

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Discount/Variety Retail

MEDIA:

Logo
Logo